vs

Side-by-side financial comparison of Immunovant, Inc. (IMVT) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.

Immunovant, Inc. is the larger business by last-quarter revenue ($8.4M vs $8.2M, roughly 1.0× NUSCALE POWER Corp). Immunovant, Inc. runs the higher net margin — -899.0% vs -3316.2%, a 2417.2% gap on every dollar of revenue. On growth, NUSCALE POWER Corp posted the faster year-over-year revenue change (1635.2% vs 140.7%). Immunovant, Inc. produced more free cash flow last quarter ($-59.8M vs $-199.9M).

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...

IMVT vs SMR — Head-to-Head

Bigger by revenue
IMVT
IMVT
1.0× larger
IMVT
$8.4M
$8.2M
SMR
Growing faster (revenue YoY)
SMR
SMR
+1494.4% gap
SMR
1635.2%
140.7%
IMVT
Higher net margin
IMVT
IMVT
2417.2% more per $
IMVT
-899.0%
-3316.2%
SMR
More free cash flow
IMVT
IMVT
$140.0M more FCF
IMVT
$-59.8M
$-199.9M
SMR

Income Statement — Q4 FY2024 vs Q3 FY2025

Metric
IMVT
IMVT
SMR
SMR
Revenue
$8.4M
$8.2M
Net Profit
$-75.3M
$-273.3M
Gross Margin
32.9%
Operating Margin
-896.2%
-6532.9%
Net Margin
-899.0%
-3316.2%
Revenue YoY
140.7%
1635.2%
Net Profit YoY
-26.7%
-1465.5%
EPS (diluted)
$-0.50
$-1.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMVT
IMVT
SMR
SMR
Q3 25
$8.2M
Q2 25
$8.1M
Q1 25
$13.4M
Q4 24
$34.2M
Q1 24
$8.4M
Q4 23
$8.9M
$4.6M
Q3 23
$3.6M
$7.0M
Q2 23
$4.1M
$5.8M
Net Profit
IMVT
IMVT
SMR
SMR
Q3 25
$-273.3M
Q2 25
$-17.6M
Q1 25
$-14.0M
Q4 24
$-75.0M
Q1 24
$-75.3M
Q4 23
$-51.4M
$-18.8M
Q3 23
$-58.7M
$-19.1M
Q2 23
$-73.9M
$-9.5M
Gross Margin
IMVT
IMVT
SMR
SMR
Q3 25
32.9%
Q2 25
22.1%
Q1 25
52.4%
Q4 24
91.1%
Q1 24
Q4 23
15.8%
Q3 23
14.5%
Q2 23
0.5%
Operating Margin
IMVT
IMVT
SMR
SMR
Q3 25
-6532.9%
Q2 25
-534.9%
Q1 25
-264.1%
Q4 24
-34.6%
Q1 24
-896.2%
Q4 23
-576.8%
-1558.2%
Q3 23
-1629.6%
-1336.9%
Q2 23
-1819.1%
-968.4%
Net Margin
IMVT
IMVT
SMR
SMR
Q3 25
-3316.2%
Q2 25
-219.0%
Q1 25
-104.7%
Q4 24
-219.1%
Q1 24
-899.0%
Q4 23
-575.6%
-411.3%
Q3 23
-1642.3%
-275.1%
Q2 23
-1818.9%
-164.3%
EPS (diluted)
IMVT
IMVT
SMR
SMR
Q3 25
$-1.85
Q2 25
$-0.13
Q1 25
$-0.11
Q4 24
$-0.77
Q1 24
$-0.50
Q4 23
$-0.36
$-0.25
Q3 23
$-0.45
$-0.26
Q2 23
$-0.57
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMVT
IMVT
SMR
SMR
Cash + ST InvestmentsLiquidity on hand
$635.4M
$691.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$617.8M
$828.7M
Total Assets
$666.4M
$883.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMVT
IMVT
SMR
SMR
Q3 25
$691.8M
Q2 25
$420.7M
Q1 25
$521.4M
Q4 24
$441.6M
Q1 24
$635.4M
Q4 23
$690.9M
$120.3M
Q3 23
$269.9M
$117.5M
Q2 23
$330.0M
$154.4M
Stockholders' Equity
IMVT
IMVT
SMR
SMR
Q3 25
$828.7M
Q2 25
$692.9M
Q1 25
$704.0M
Q4 24
$618.7M
Q1 24
$617.8M
Q4 23
$679.3M
$93.5M
Q3 23
$251.8M
$105.9M
Q2 23
$299.9M
$110.1M
Total Assets
IMVT
IMVT
SMR
SMR
Q3 25
$883.1M
Q2 25
$606.5M
Q1 25
$618.1M
Q4 24
$544.7M
Q1 24
$666.4M
Q4 23
$711.4M
$224.9M
Q3 23
$292.1M
$308.5M
Q2 23
$351.2M
$309.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMVT
IMVT
SMR
SMR
Operating Cash FlowLast quarter
$-59.7M
$-199.8M
Free Cash FlowOCF − Capex
$-59.8M
$-199.9M
FCF MarginFCF / Revenue
-714.4%
-2425.1%
Capex IntensityCapex / Revenue
1.8%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMVT
IMVT
SMR
SMR
Q3 25
$-199.8M
Q2 25
$-33.3M
Q1 25
$-22.8M
Q4 24
$-26.4M
Q1 24
$-59.7M
Q4 23
$-47.1M
$-73.2M
Q3 23
$-60.1M
$-27.7M
Q2 23
$-47.4M
$-39.2M
Free Cash Flow
IMVT
IMVT
SMR
SMR
Q3 25
$-199.9M
Q2 25
Q1 25
$-22.9M
Q4 24
$-26.5M
Q1 24
$-59.8M
Q4 23
$-47.2M
$-73.3M
Q3 23
$-60.1M
$-27.7M
Q2 23
$-47.4M
$-40.5M
FCF Margin
IMVT
IMVT
SMR
SMR
Q3 25
-2425.1%
Q2 25
Q1 25
-170.9%
Q4 24
-77.3%
Q1 24
-714.4%
Q4 23
-528.7%
-1606.6%
Q3 23
-1682.4%
-399.0%
Q2 23
-1166.4%
-698.9%
Capex Intensity
IMVT
IMVT
SMR
SMR
Q3 25
0.9%
Q2 25
Q1 25
0.5%
Q4 24
0.1%
Q1 24
1.8%
Q4 23
1.5%
1.1%
Q3 23
1.0%
0.8%
Q2 23
1.1%
21.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMVT
IMVT

Segment breakdown not available.

SMR
SMR

Power Plant And NPM Engineering Design And Licensing Services And Fees$8.0M97%
Other$208.0K3%

Related Comparisons